CN104711331A - Cancer pathologic evolution early-stage Gankyrin gene mRNA level in-situ hybridization detection kit, detection method and applications thereof - Google Patents
Cancer pathologic evolution early-stage Gankyrin gene mRNA level in-situ hybridization detection kit, detection method and applications thereof Download PDFInfo
- Publication number
- CN104711331A CN104711331A CN201310670459.8A CN201310670459A CN104711331A CN 104711331 A CN104711331 A CN 104711331A CN 201310670459 A CN201310670459 A CN 201310670459A CN 104711331 A CN104711331 A CN 104711331A
- Authority
- CN
- China
- Prior art keywords
- hybridization
- cancer
- test kit
- probe
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an in-situ hybridization detection kit, which comprises a hybridization probe and a marker, and further discloses a method utilizing the in-situ hybridization detection kit to detect the Gankyrin gene RNA expression change, which is closely related with the pathologic evolution in the early stage of cancer. The method comprises the following steps: (1) under a condition that a hybridization probe and a target sequence can form a stable hybridization complex, contacting RNA to be detected in a substrate with a hybridization probe so as to form a hybridization complex; (2) detecting the obtained hybridization complex. The provided kit and detection method can detect the expression quantity of Gankyrin gene in the RNA level, can detect the cancer in an earlier stage compared with the medical imaging technology and conventional clinical biochemical index detection, can achieve real RNA level screening in the early stage of cancer, moreover, have the advantages of simpleness, convenience, and low cost, and thus are convenient to promote and use in county/district hospitals.
Description
Technical field
The present invention relates to field of biological detection, more particularly, relate to the correlation detection technology changing (in Pathologic process) with cancer Pathologic mrna expression in early stage.
Background technology
According to the data that domestic and international authoritative institution provides, the newly-increased number of the annual cancer of China reaches 3,120,000, death toll nearly 2,600,000, patient is more than more than 700 ten thousand, the annual newly-increased cancer patients 8,000,000 in the whole world, death toll is close to more than 800 ten thousand, and patient about has more than 8,400 ten thousand people, to double to the above number of the year two thousand twenty, this is one group of fearful numeral.Cancer diagnosis and treatment cost is more and more higher, (poor regional possible higher by the year medical expense 200,000 of cancer patients, developed regions may exceed 200,000 far away), more than 700 ten thousand patients, annual cost is 1.4 trillion Renminbi, deduction cost 35% about 400,000,000,000, about has 1,000,000,000,000 Renminbi to consume in vain every year.And cancer patients's major part can be dead soon after the treatment.Therefore, existing clinical cancer diagnosis and treatment pattern must change, innovative point of the present invention accomplishes preventative examination in advance, the mrna expression amount of examination Gankyrin gene before knurl block does not occur, to expression amount reduction person, the preventative regulation and control of timely intervention and prophylactic treatment, accomplish preventiveing treatment of disease of gene level cancer.
It is failure that eight units such as U.S. sanitary research institute, cancer research institute, Disease Control and Prevention Centers in 2005 have done in anticancer Great War, conclusion is that cancer mortality does not reduce, and it lists and causes several factors of anticancer Great War failure to be: 1. tumour cell heterogeneity (polymorphism); 2. tumor cell drug resistance; 3. Anti-Cancer Drug Design thinking imperfection (animal model designs not science) etc.Meanwhile, the measure of answering re-examine existing diagnosis and treatment cancer is also proposed in this report.
The present inventor finds in studying for a long period of time, and the major reason causing cancer mortality not fallen to accomplish real early diagnosis.Diagnosing cancer is carried out according to existing clinical medicine image (B ultrasonic, CT, Magnetic resonance imaging etc.) and with other biochemistry (cancer antigen, carcinomebryonic antigen, carbohydrate hormone, the cytolemma factor, nuclear factor, cell streaming technology) index, all that tumour forms rear diagnosis, the former will learn change or existing occupying lesion in a organized way, and the latter's major part is the marker that tumour forms rear secreted, release or tumour.Traditional clinical idea thinks that occupancy cancer block is the diagnosis belonging to early-stage cancer under 2 centimeters, this concept is worth conscientiously discussing, it is rigorous not that less than 2 centimeters early stage these of cancer block genus define science, analyze from cytology angle, the lump of 1 centimeter about has 100,000,000 tumour cells, its three-dimensional cell superposition number of the lump of 2 centimeters is far above 200,000,000 tumour cells, produce and formed the cancer block of 2 centimeters from pre-cancerous to mono-clonal cancer cells, its Pathologic process is quite long, it may be 5 years or 10 years, or even more than 10 years (except special case), what be difficult to confirmation is in this Pathologic process, lump is the unique spot of cancer and independent focus, possible cancer cells moves to other tissue or organ growth already.Clinical study confirms already, once while forming lump, other cancer cells moves to other position clonal growth by different approaches, once after excision primary tumor, other organ recurrence stove or multiple cancer block stove are successively formed.Therefore, define whether in early days with the cancerous swelling piece size of less than 2 centimeters clinically, rigorous not (some case, when finding primary lesion, find metastatic lesion simultaneously, not in the content of our statement), be at this moment late diagnosis and treatment of late stage in fact, this is the true cause causing cancer mortality not fallen.
Along with molecular biotechnology is day by day perfect, functional genomics, the deep expansion of the research such as cancer gene group, in order to seek more early stage diagnosing cancer, Therapeutic cancer and preventing cancer, makes great progress.So far, we likely do more accurate early screening and diagnosis on the one-level functional transcription product (mRNA level in-site or microRNA) of gene, form (mono-clonal) front, just can accomplish early prediction and examination at pre-cancerous or cancer cells.
Large quantifier elimination confirms that Gankyrin gene is in pre-cancerous up-regulated (liver cancer, mammary cancer lung cancer, colorectal carcinoma, cancer of the stomach, carcinoma of the pancreas, prostate cancer, bone marrow cancer, thyroid carcinoma), Gankyrin gene is proto-oncogene, and its expression is increased and caused cell carcinogenesis.Experimental study finds further, suppresses the expression of Gankyrin that drug-induced Murine cancer incidence then can be made obviously to reduce.And Gankyrin gene mRNA expresses all high expression levels in various ethnic group (white man, Black people, yellow) cancer patients's peripheral blood leucocyte.
More the present invention selects to organize clinical samples (cancer patient, high risk population, normal control) and adopts nucleic acid hybridization in situ technology and the early warning of ImmunohistochemistryMethods Methods to Gankyrin gene mRNA cancer to carry out detection analysis.The present inventor finds that Gankyrin gene mRNA has obvious expression amount to change cancer patient, cancer high risk population, normal control people under study for action, using Gankyrin gene mRNA as canceration pathological change screening indexes in early stage, there is very important clinical diagnosis meaning.Do in the Preventive early warning after the examination of pre-cancerous pre-cancerous and cancer therapy and also have very important clinical meaning.
Contriver is in long-term research, draw a kind of new concept, the clinical diagnosis and treatment pattern of cancer and other clinical major disease must change, only can not stop existing treating the disease affected (diagnosis and treatment after morbidity), accomplish preventative diagnosis and treatment, accomplish to preventive treatment of disease, only in this way could reduce the M & M of major disease, reduce social cost and medical treatment cost.Therefore, contriver in the rna level kit for screening and medicine of development and production major disease, theoretical and technically all innovate.Particularly screen clinical samples (normal population, cancer high risk population, tumour patient), breach the consistency Research idea that healthy tissues compares with tumor tissues, the rna level become before finding and develop cancer, develop closely related with cancer early gene physiopathology, and the extremely important target of clinical meaning (disease gene), tumour is clinically formed the preventative diagnosis and treatment that rear diagnosis and treatment pattern brings up to tumour, has striven for the Time and place of tumor diagnosis and treatment, reached preventing cancer.
At present, the analytical technologies such as the Northern hybridization of Gankyrin expression profiling method, gene chip, real-time fluorescence quantitative PCR and Solexa order-checking, and these methods are used for scientific research aspect, be not suitable with clinical application, and detect mRNA more more scientific than DNA analysis (DNA analysis major part in the presentation of susceptibility, mRNA is the embodiment of DNA function), more reliable than analysis of protein (contriver finds mRNA and protein transcription and expresses on space-time in the research of employing Double Labelling Technique, sometimes asynchronous).The detection technique of hybridization in situ technique and groupization immunization method detection Gankyrin gene mRNA levels expression amount and test kit is adopted to have no report according to existing documents and materials.
The present inventor is in the requirement for innovations, devise (cancer patients, high risk population, normal control) different pieces of information example group, detect with hybridization in situ technique, result shows above cancer patient Gankyrin gene mRNA all high expression levels, high risk population has and expresses 10-25% in various degree, and normal control is all zero expression.Show that Gankyrin gene mRNA is the important symbol thing of pre-cancerous pre-cancerous examination.
Hybridization in situ technique (in situ hybridization) is combined with Cytochemical Technique by molecular biology, with the nucleic acid molecule marked for probe, in the technology of histocyte in situ detection specific nucleic acid molecules.Its principle makes containing distinguished sequence, the single nucleic acid strands (i.e. probe) passing through mark, hybridize with the complementary nucleic acid strand in histocyte and target nucleic acid under optimum conditions, with radioautograph or immunocytochemistry, label probe is detected again, thus show special DNA or RNA molecule at cell in-situ.
The probe of in situ hybridization is that the unknown but nucleic acid molecule that molecule is known of the molecule of known array or sequence is (though this molecule full sequence indefinite, but known its for what target molecule), the kind of probe can be divided into again DNA probe, cDNA probe, cRNA probe and synthetic oligonucleotide probe by properties of nucleic acids difference.For the ease of spike, probe must be marked by certain means, is beneficial to later detection.Conventional marker comprises radionuclide and the large class of non-radioactive marker two.Conventional isotopic label has
3h,
35s,
125i and
32p.The advantages such as susceptibility is high although isotopic label has, back end is comparatively clear, because radio isotope all can damage human and environment, have the trend replaced by heterotope recently.The most frequently used at present in non-isotopic labels have vitamin H, digoxin and fluorescein three kinds.The method detecting these markers is all extremely sensitive.
Can be divided into DNA-DNA again according to probe used and the difference that will detect nucleic acid, RNA-DNA, RNA-RNA are hybridized.No matter but the hybridization of any form, all have to pass through five large processes, namely histiocytic fixing, prehybridization, hybridization, flushing and display.The present invention adopts the Crossing system of RNA-RNA, and the probe (RNA) of synthesis and the target RNA detected are the principles adopting base complementrity (hybridize complementary), simultaneously through long-time research with observe, start and termination place residue does not affect the result detected.
In view of the diagnosis (medical imaging and biochemical indicator thing are all the diagnosis after tumour is formed) of current pre-cancerous is clinically late diagnosis, treatment is also treatment of late stage, is also the treatment pattern causing mortality ratio not fallen.Original intention of the present invention wants to improve at present the diagnosis and treatment pattern of major disease clinically, become preventative from treating the disease affected to preventive treatment of disease, reach preventative diagnosis and treatment, become mRNA level in-site before current medical imaging means and numerous biochemical marker cannot be detected cancer and quantize change technology, do the technological breakthrough of novelty, before cancer is provided, become mRNA level in-site examination technology.Become the technology of the real early screening of mRNA level in-site before making to have had clinically a new cancer, the diagnosis and treatment for clinical cancer are raced against time and space.
In sum, first object of the present invention is to provide a kind of hybridization in situ detection kit, and it comprises in situ hybridization detection probes and marker.Secondly, the present invention also will provide mentioned reagent box for shifting the relevant in situ hybridization detection method of early warning after the examination in early stage of cancer Pathologic and treatment.
Summary of the invention
For realizing object of the present invention, technical scheme of the present invention is as follows:
First the present invention provides a kind of hybridization in situ detection kit, it comprises hybridization probe and marker, wherein, described hybridization probe has sequence table SEQ ID NO:D83197 respectively, nucleotide sequence length is 1544bp, CDS sequence is 99...779bp, and probe total length 480bp to take from CDS one section, and described hybridization probe sequence is as shown in SEQ ID NO.1.
A preferred version of test kit of the present invention is, described marker is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, fluorescein, enzyme and nano material.
A preferred version of test kit of the present invention also comprises hybridization solution.
A preferred version of test kit of the present invention also comprises toughener.
A preferred version of test kit of the present invention also comprises developer.
Cancer Pathologic of the present invention Gankyrin gene mRNA in early stage kit for screening using value is, to the examination in early stage of cancer Pathologic, and Preventive, diffusion prediction occurring after canceration or after treatment, coordinate clinical treatment further.
The present invention also provides a kind of detection method of Gankyrin in situ hybridization, comprises the following steps:
(1) under hybridization probe recited above and target sequence can form the condition of stable hybridization complex, RNA to be measured in substrate is contacted with hybridization probe, form hybridization complex; With
(2) described hybridization complex is detected.
Detection method of the present invention, is wherein preferably, and the described condition forming stable hybridization complex is: the temperature of nucleic acid hybridization is 42 DEG C; The time of nucleic acid hybridization is 16-24 hour.
Detection method of the present invention, is wherein preferably, and described substrate selects blood leucocyte sample or other organ-tissue cell specimen of people.More preferably, described blood preparation or other organ-tissue cell specimen are from cancer patients, high risk population, healthy normal population.
Detection kit of the present invention adopts nucleic acid hybridization technique and groupization immunization method to combine, with Gankyrin gene mRNA for detected object, synthesising probing needle is Gankyrin gene recombination complementary sequence, and the substrate of detection is the expression amount of blood of human body sample white corpuscle or histiocytic Gankyrin gene mRNA.The display packing of hybridization in situ technique can provide sxemiquantitative or the quantitative expression deciding degree of Gankyrin gene mRNA.Judge the expression amount of above mRNA according to immunohistochemical visualization after hybridization, normal people Gankyrin zero expresses, and cell does not develop the color; The low expression of high risk population, a small amount of cell dyeing; Cancer patient high expression level, cell dyes in a large number.
The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, the compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that molecular biology insider all knows, and concrete operation step carries out quantitative analysis, report the test under sample disposal, prehybridization, hybridization, immunohistochemical staining, mirror, and the concrete steps of wherein hybridizing comprise:
1). sample to be measured is put into reactive tank;
2). instrument discards liquid automatically, automatically adds Digestive system;
3). instrument discards liquid automatically, fixing automatically;
4). instrument discards liquid automatically, automatic prehybridization (42 DEG C);
5). instrument discards liquid automatically, automatically cleans;
6). instrument discards liquid automatically, automatically hybridization (42 DEG C);
7). instrument discards liquid automatically, automatically cleans;
8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);
9). instrument discards liquid automatically, automatically cleans, colour developing;
10). take out mounting microscopy.
The scheme of a preferred embodiment of the present invention is: with the nucleic acid probe digoxigenin labeled (cDNA of digoxigenin labeled of Gankyrin gene mRNA synthesis, RNA and oligonucleotide probe, not only probe has biotin labeling advantage, also overcoming biotin labeled probe is organized Endogenous Biotin to do the shortcomings such as sorrow in crossover process in position), this hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized, develop the color by the method for immunohistochemical methods again, in existence and the location of light Microscopic observation RNA, according to the cell count of dyeing, judge the expression amount of object RNA.
The inventive method is nucleic acid hybridization in situ technology conventional at present, the method is by the Gankyrin gene mRNA expression amount in detection substrate cell, be used for determining the mRNA variable quantity in cancer Pathologic early stage, whether early warning cancer occurs and the prediction of whether Preventive after cancer patients's treatment.Because Gankyrin gene mRNA is expressed normal people zero, Gankyrin gene is that proto-oncogene has carcinogenesis, if expression amount increase illustrate cancer occurred or risk of developing cancer high, get involved early period regulation and treatment early clinically, suppress the expression of Gankyrin gene, keep cancer suppressor gene and oncogene physiological equilibrium, preventing cancer occurs.
A test kit can many person-portions use or person-portion use.
The present invention has following beneficial effect:
Clinical meaning of the present invention is the change of Gankyrin gene mRNA expression amount in more early stage tracing detection cancer pathology evolution process, and early warning cancer occurs, development trend.Diagnostic kit of the present invention is with other detects and cancer markers clinically, and medical imaging inspection has and shows difference.The present invention can detect the unconventionality expression of Gankyrin gene in mRNA level in-site, before medical imaging inspection does not find the recurrence of occupancy carninomatosis stove, before cancer biochemical indicator does not produce extremely, also before not forming tumour, the information acquisition of Gankyrin abnormal gene expression can be accomplished early, to the early warning that clinical cancer patient one is real, so just likely implement the early screening of cancer, early prevention, early treatment, likely from source, thoroughly effect a radical cure cancer cachexia.
In addition, test kit provided by the invention has feature that is highly sensitive, high specificity, and meanwhile, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.
Accompanying drawing explanation
Fig. 1 is that illustration is implemented in Gankyrin gene mRNA in situ hybridization of the present invention;
Fig. 2 is cancer patient Gankyrin gene mRNA expression picture in the embodiment of the present invention;
Fig. 3 is high risk population Gankyrin gene mRNA expression picture in the embodiment of the present invention;
Fig. 4 is normal people Gankyrin gene mRNA expression picture in the embodiment of the present invention.
Embodiment:
Below in conjunction with embodiment, further illustrate content of the present invention.Should be appreciated that, the following examples for illustration of and non-limiting content of the present invention, any pro forma change or flexible will fall into protection scope of the present invention.
Embodiment 1
Conventionally prepare the in situ hybridization test kit of the present embodiment, this test kit comprises with hybridization probe, marker, the specification sheets of the design of Gankyrin gene mRNA, wherein:
The probe mark thing optionally Gaoxin of the present embodiment.
Test kit hybridization solution forms:
/ box colourless transparent liquid managed by Digestive system 100 μ L/ pipe 1
/ box colourless transparent liquid managed by protection liquid 100 μ L/ pipe 1
/ box colourless transparent liquid managed by prehybridization solution 1300 μ L/ pipe 2
/ box colourless transparent liquid managed by justice hybridization solution 10 μ L/ pipe 1
/ box colourless transparent liquid managed by antisense hybridization liquid 10 μ L/ pipe 1
/ box colourless transparent liquid managed by confining liquid 1000 μ L/ pipe 1
/ box colourless transparent liquid managed by alkaline phosphatase antibodies 1 μ L/ pipe 1
/ box yellow liquid managed by developer A 175 μ L/ pipe 1
/ box colourless transparent liquid managed by developer B 320 μ L/ pipe 1
Light yellow or the colourless transparent liquid of damping fluid I 90mL/ bottle 1 bottle/box
Light yellow or the colourless transparent liquid of damping fluid II 80mL/ bottle 1 bottle/box
Light yellow or the colourless transparent liquid of damping fluid III 20mL/ bottle 3 bottle/box
Light yellow or the colourless transparent liquid of damping fluid IV 90mL/ bottle 1 bottle/box
Stationary liquid 90mL/ bottle 1 bottle/box colourless transparent liquid
Positive control sample 6/box.
Reagent preparation working concentration
1). 10 × damping fluid I tri-distilled water is diluted to 1 × damping fluid I by 1:10;
2). 20 × damping fluid II tri-distilled water is diluted to 2 × damping fluid II by 1:10;
0.2 × damping fluid II is diluted to by 1:100; 0.1 × damping fluid II is diluted to by 1:200;
3). 10 × damping fluid III tri-distilled water is diluted to 1 × damping fluid III by 1:10;
4) .10 × damping fluid IV with tri-distilled water by 1:10 be diluted to × damping fluid IV (get 1#, each 10mL of 2#, 3#, add water to 100mL both can).
Embodiment 2
Application nucleic acid hybridization in situ detection method is to the implementation process of each group of blood preparation Gankyrin gene mRNA expression amount:
1). get sample to be measured two;
2). in glass jar, add Digestive system (Digestive system 100 μ L adds 1 × damping fluid I 99.9ml, is working concentration) 50 ml, 37 DEG C of water-bath preheating 10min, put 16 slides into, 37 DEG C of process 12 min, then use 1 × damping fluid I to wash 5min;
3). (protection liquid 1ml adds 1 × damping fluid to the protection liquid with 0.2%
, 99ml is working concentration) and wash 10min, tri-distilled water is washed more than 5min(process and is all carried out at glass jar), take out slide, allow its seasoning;
4). slide is put into moisture preservation box, and add prehybridization solution 25 μ L/ sheet (being added in the place of cell), covered, covers tightly moisture preservation box, is placed on more than 3h in 42 DEG C of constant water bath box;
5). take out slide, discard cover glass, slide is put into glass jar, respectively wash 2min with the ethanol of 70%, 90%, 95%, take out, seasoning;
6). slide is put into moisture preservation box, and one adds just hybridization solution 25 μ L/ sheet, and another adds antisense hybridization liquid 25 μ L/ sheet, and covered, covers tightly moisture preservation box, is placed on 16-24h in 42 DEG C of constant water bath box;
7). take out slide, discard cover glass, slide is put into glass jar:
Twice is washed with 2 × damping fluid II, each 15min in 42 DEG C of constant water bath box;
Wash once with 0.2 × damping fluid II in 42 DEG C of constant water bath box, each 15min;
Twice is washed with 0.1 × damping fluid II, each 15min in 42 DEG C of constant water bath box;
8). wash 30s with 1 × damping fluid III, take out slide, seasoning;
9). slide is put into moisture preservation box, adds 0.5% confining liquid (1ml confining liquid adds 5ml 1 × damping fluid III) 100 μ L/ sheet, cover tightly moisture preservation box, at room temperature act on 30min.(this step does not need to add cover glass);
10). take out slide, wash 30s with 1 × damping fluid III, seasoning;
11). slide is put into moisture preservation box, add X-AP antibody and (get a pipe alkaline phosphatase antibodies, add 1.8ml 1 × damping fluid III wherein) 100 μ L/ sheets, cover tightly moisture preservation box and at room temperature act on 30min, time can not be long, otherwise can produce false positive (this step does not need to add cover glass);
12). take out slide, wash 3 times with 1 × damping fluid III, each 15min;
13). wash 2min with 1 × damping fluid IV, add developer (developer A73.3 μ L, developer B157.5 μ L is added in 30mL 1 × damping fluid IV, mixing), room temperature more than lucifuge 16h to 18h;
14). wash 5min with tri-distilled water, seasoning, (1 × damping fluid I adding 10% with glycerine mixes) mounting microscopy.
Nucleic acid hybridization in situ detection method of the present invention is by goal gene digoxigenin labeled, become RNA nucleic acid probe, the RNA nucleic acid to be measured of probe and human leukocytes is hybridized, develop the color by the method for immunohistochemical methods again, therefore in existence and the location of light Microscopic observation RNA, according to the cell count of dyeing, judge the expression amount of object RNA.
Cancer patient 20, high risk population 20, Normal group 20.The peripheral blood 3-5 milliliter (separation white corpuscle) taking out all people to be checked does in situ hybridization.Result represents, all cancer patients Gankyrin gene mRNAs zero are expressed, cell dye-free; High risk population expresses and slightly reduces, and decimal dyes; Normal group Gankyrin gene mRNA high expression level, cell dyes in a large number, and concrete outcome is shown in Fig. 2, Fig. 3, Fig. 4.
| Cancer occurrence numbers | Expression amount % | High-risk number | Expression amount % | Normal number | Expression amount % |
| 1 | 80 | 1 | 18 | 1 | 0 |
| 2 | 76 | 2 | 23 | 2 | 0 |
| 3 | 80 | 3 | 0 | 3 | 0 |
| 4 | 82 | 4 | 12 | 4 | 0 |
| 5 | 72 | 5 | 22 | 5 | 0 |
| 6 | 78 | 6 | 18 | 6 | 0 |
| 7 | 82 | 7 | 24 | 7 | 0 |
| 8 | 84 | 8 | 20 | 8 | 0 |
| 9 | 76 | 9 | 12 | 9 | 0 |
| 10 | 72 | 10 | 16 | 10 | 0 |
| 11 | 82 | 11 | 0 | 11 | 0 |
| 12 | 80 | 12 | 18 | 12 | 0 |
| 13 | 72 | 13 | 13 | 13 | 0 |
| 14 | 74 | 14 | 20 | 14 | 0 |
| 15 | 76 | 15 | 0 | 15 | 0 |
| 16 | 78 | 16 | 20 | 16 | 0 |
| 17 | 80 | 17 | 16 | 17 | 0 |
| 18 | 84 | 18 | 16 | 18 | 0 |
| 19 | 82 | 19 | 20 | 19 | 0 |
| 20 | 84 | 20 | 22 | 20 | 0 |
(note: cancer patient has clinical all kinds of cancer; High risk population has selected slow liver liver cirrhosis; Normal people company personnel, clinical health check-up normal people).
SEQUENCE LISTING
<110> Rui Qu biotechnology (Shanghai) Co., Ltd.
The hybridization in situ detection kit of <120> cancer Pathologic Gankyrin gene mRNA levels in early stage and detection method and application
<130> 、
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 480
<212> DNA
<213> Homo sapiens
<400> 1
taatggtctg caacctggcc tacagcggga agctggaaga gttgaaggag agtattctgg 60
ccgataaatc cctggctact agaactgacc aggacagcag aactgcattg cactgggcat 120
gctcagctgg acatacagaa attgttgaat ttttgttgca acttggagtg ccagtgaatg 180
ataaagacga tgcaggttgg tctcctcttc atattgcggc ttctgctggc cgggatgaga 240
ttgtaaaagc ccttctggga aaaggtgctc aagtgaatgc tgtcaatcaa aatggctgta 300
ctcccttaca ttatgcagct tcgaaaaaca ggcatgagat cgctgtcatg ttactggaag 360
gcggggctaa tccagatgct aaggaccatt atgaggctac agcaatgcac cgggcagcag 420
ccaagggtaa cttgaagatg attcatatcc ttctgtacta caaagcatcc acaaacatcc 480
Claims (9)
1. a hybridization in situ detection kit, comprises hybridization probe and marker, it is characterized in that, described hybridization probe sequence is as shown in SEQ ID NO.1.
2. test kit as claimed in claim 1, it is characterized in that, described marker is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, fluorescein, enzyme and nano material.
3. test kit as claimed in claim 1, it is characterized in that, this test kit also comprises hybridization solution.
4. test kit as claimed in claim 1, it is characterized in that, this test kit also comprises synergistic agent.
5. test kit as claimed in claim 1, it is characterized in that, this test kit also comprises developer.
6. a Gankyrin gene hybridization in situ detection method, is characterized in that, the method comprises the following steps:
(1) under hybridization probe according to claim 1 and target sequence can form the condition of stable hybridization complex, RNA to be measured in substrate is contacted with hybridization probe, form hybridization complex; With
(2) described hybridization complex is detected.
7. detection method as claimed in claim 6, it is characterized in that, the described condition forming stable hybridization complex is: the temperature of nucleic acid hybridization is 42 DEG C; The time of nucleic acid hybridization is 16-24 hour.
8. detection method as claimed in claim 6, is characterized in that, described substrate choosing is human peripheral blood white corpuscle sample.
9.Gankyrin gene detects the application in cancer Pathologic in situ hybridization in early stage test kit in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310670459.8A CN104711331A (en) | 2013-12-11 | 2013-12-11 | Cancer pathologic evolution early-stage Gankyrin gene mRNA level in-situ hybridization detection kit, detection method and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310670459.8A CN104711331A (en) | 2013-12-11 | 2013-12-11 | Cancer pathologic evolution early-stage Gankyrin gene mRNA level in-situ hybridization detection kit, detection method and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104711331A true CN104711331A (en) | 2015-06-17 |
Family
ID=53411049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310670459.8A Pending CN104711331A (en) | 2013-12-11 | 2013-12-11 | Cancer pathologic evolution early-stage Gankyrin gene mRNA level in-situ hybridization detection kit, detection method and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104711331A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111596059A (en) * | 2020-05-19 | 2020-08-28 | 上海长海医院 | Application of Gankyrin protein as novel molecular marker in prostate cancer prognosis evaluation |
-
2013
- 2013-12-11 CN CN201310670459.8A patent/CN104711331A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111596059A (en) * | 2020-05-19 | 2020-08-28 | 上海长海医院 | Application of Gankyrin protein as novel molecular marker in prostate cancer prognosis evaluation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102559881A (en) | Messenger ribonucleic acid (mRNA) level in-situ hybridization detection kit for neoplasia early stage of intracranial glioma, and detection method and application | |
| CN104711331A (en) | Cancer pathologic evolution early-stage Gankyrin gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN104711336A (en) | Solid tumor pathologic evolution early-stage GADD45G gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN101429550B (en) | Synthetic detection kit for hybridization in situ and detection method | |
| CN102559887A (en) | Messenger ribonucleic acid (mRNA) level in-situ hybridization detection kit for JAGGED1 in early stage of pathological change of breast cancer bone metastasis, and detection method and application | |
| CN104131064A (en) | In-situ hybridization detection kit of miR-378 in early stage of pathologic evolution of gastric cancer, detection method and application | |
| CN102533990B (en) | In situ hybridization detection kit for mRNA level at precancerous stage of breast cancer, detection method and application thereof | |
| CN104711326A (en) | Multi-cancer pathologic evolution early-stage Bmi1 gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN104711335A (en) | Cancer metastasis pathologic evolution early-stage HOPX gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN104711329A (en) | Cancer metastasis pathologic evolution early-stage IDH1 gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN104711337A (en) | HELQ gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN104711327A (en) | Cancer pathologic evolution early-stage GPR116 gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN104711325A (en) | AGPS gene mRNA level in-situ hybridization detection kit, detection method and applications thereof | |
| CN102559884A (en) | LET-7micro ribose nucleic acid (MIRNA) level in-situ hybridization detection kit for pathologic evolution early stage of various cancer, and detection method and application | |
| CN102605056A (en) | In-situ hybridization assay kit for mRNA level of premalignant pancreatic cancer ATDC (telangiectasia group D associated protein) gene as well as assay method and application | |
| CN102533976A (en) | Kit and method for detecting horizontal in situ hybridization of MICRORNA-21 at the early pathological evolution stage of a variety of cancers and application thereof | |
| CN102605060A (en) | In-situ hybridization assay kit for premalignant lung cancer 14-3-3thta level as well as assay method and application | |
| CN104131065A (en) | In-situ hybridization detection kit of AFPR gene in early stage of pathologic evolution of hepatic carcinoma, detection method and application | |
| CN104140999A (en) | MRNA level in-situ hybridization detection kit of AE1 gene in earlier stage of pathologic evolution of stomach cancer, detection method and application | |
| CN102628078A (en) | MicroRNA-155 level in various types of cancerous lesions prophase in situ hybridization detection kit, detection method and application thereof | |
| CN102443641A (en) | Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof | |
| CN104140998A (en) | In-situ hybridization detection kit of miR-886-3P level in earlier stage of pathologic evolution of small cell lung cancer, detection method and application | |
| CN104711321A (en) | Stomach cancer pathologic evolution early-stage miRNA-200c level in-situ hybridization detection kit, detection method and applications thereof | |
| CN102443644A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-29A level at pathologic evolution early stage of colon cancer as well as microRNA-29A in-situ hybridization detection method and application of microRNA-29a to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102443647A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-145 level at pathologic evolution early stages of various colon cancers as well as microRNA-145 in-situ hybridization detection method and application of microRNA-145 to preparation of in-situ hybridization detection kit for colon cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150617 |
|
| WD01 | Invention patent application deemed withdrawn after publication |